Knee Osteoarthritis, PRP Injection
Conditions
Keywords
Knee Osteoarthritis, PRP injection
Brief summary
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.
Detailed description
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Treatment options include weight loss, anti-inflammatory and pain-relieving medications, physical rehabilitation, and intra-articular injections of corticosteroids or hyaluronic acid. However, these methods often have limited efficacy or may cause side effects. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. However, there is still lack of strong evidence of the therapeutic effects of PRP injection in knee OA. Therefore, there is a need to investigate novel therapies for knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis. Patients with mild to moderate knee osteoarthritis who have experienced symptoms for more than three months. 30 participants will be recruited and randomly divided into three groups: the SRF group, the PRP group, and a control group. Each participant will receive knee intra-articular injections as part of a three-month treatment regimen, with one injection per month for a total of three injections. Patients will be evaluated before the trial, and at one, two, three, and six months after the injections. Clinical outcomes will be assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale, the sit-to-stand test, and the Visual Analog Scale (VAS) for pain. The study aims to confirm the clinical efficacy of SRF in treating degenerative knee osteoarthritis.
Interventions
PROCEDURELyophilized self growth factor
Knee Intraarticular injection with Lyophilized self growth factor
PROCEDUREPlatelet-Rich Plasma(PRP)
Knee Intraarticular injection with Lyophilized self growth factor
PROCEDUREPlacebo
Knee Intraarticular injection with normal saline
Sponsors
Tri-Service General Hospital
Study design
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, aged over 20 and under 80. * Consciousness clear and able to communicate. * Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months. * X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3). * Knee joint pain with a Visual Analogue Scale (VAS) score greater than 4.
Exclusion criteria
* Severe knee osteoarthritis (Kellgren-Lawrence grade 4). * Currently systemic infection. * Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment. * The treated joint has undergone joint replacement surgery or major surgery. * Severe knee deformity or instability. * Known history of cancers, rheumatoid arthritis, platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acute or chronic infectious diseases, chronic liver disease, or poorly controlled cardiovascular disease or diabetes. * Currently receiving anticoagulant therapy. * Long-term or excessive use of aspirin or vitamin E. * History of HIV/AIDS, syphilis, or other legally notifiable infectious diseases. * Pregnant or breastfeeding women, or women and men of childbearing potential who are unable to use effective contraception during the treatment period. * Deemed unsuitable for participation in the trial by the principal investigator. * Unable to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index | Pre-treatment, 1st month, 2nd month, 3rd month, 6th month | The structure and function of the knee joint are assessed from three main aspects: pain, stiffness, and joint function, with a total of 24 items. The pain section consists of 5 items (24 points in total), the stiffness section has 2 items (8 points in total), and the joint function section includes 17 items (68 points in total). A lower score indicates more severe pain, stiffness, and a higher degree of disability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Scale | Pre-treatment, 1st month, 2nd month, 3rd month, 6th month | Change from baseline of pain on 1st month, 2nd month, 3rd month, 6th month after injection. Pain severity was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain |
| The intermittent and constant pain score , ICOAP | Pre-treatment, 1st month, 2nd month, 3rd month, 6th month | The content is divided into two subcategories: continuous pain (5 items) and intermittent pain (6 items), with a total of 11 items. Each item is scored from 0, representing no pain, to 4, representing extreme pain. A higher score indicates more severe pain. The Chinese version has reliable validity and reliability. |
| Timed Up and Go test | Pre-treatment, 1st month, 2nd month, 3rd month, 6th month. | Align the chair legs with the starting baseline and place a cone 3 meters ahead. The participant sits in the chair with their feet naturally bent, stands up comfortably, walks forward for 3 meters, turns around, and walks back to sit down. The time taken to complete the task is recorded. This test has good validity and reliability for assessing the mobility of patients with degenerative knee osteoarthritis. |
Countries
Taiwan
Contacts
Primary ContactYu Chi Su,, MD
Outcome results
None listed